NuVasive Announces First Quarter 2020 Financial Results
SAN DIEGO, May 6, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2020.
First Quarter 2020 Highlights
-- Revenue decreased -5.4% to $259.9 million, or -5.1% on a constant
currency basis;
-- GAAP operating margin of 10.9%; Non-GAAP operating margin of 16.9%; and
-- GAAP diluted earnings per share of $0.10; Non-GAAP diluted earnings per
share of $0.48.
"First and foremost, I want to recognize the healthcare professionals who are battling COVID-19 on the front lines and whose work is truly heroic during this global healthcare crisis," said J. Christopher Barry, chief executive officer of NuVasive. "Additionally, I am proud of the resiliency demonstrated by NuVasive employees, as the Company remains committed to supporting our surgeon partners and their patients during this time.
"NuVasive's first quarter performance was consistent with the preliminary revenue results provided in the business update shared last month," Barry continued. "The Company began the quarter positioned to build upon the financial momentum delivered last year, but faced a decline in elective procedure volumes due to the COVID-19 pandemic. However, with a strong cash position, dedicated team and innovative technology in our pipeline, we are confident in the long-term trajectory of the business and our purpose to transform surgery, advance care and change lives."
A full reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this news release.
First Quarter 2020 Results
NuVasive reported first quarter 2020 total revenue of $259.9 million, a -5.4% decrease compared to $274.8 million for the first quarter 2019. On a constant currency basis, first quarter 2020 total revenue decreased -5.1% compared to the same period last year.
For the first quarter 2020, both GAAP and non-GAAP gross profit was $188.0 million and GAAP and non-GAAP gross margin was 72.3%. These results compared to GAAP and non-GAAP gross profit of $200.3 million and GAAP and non-GAAP gross margin of 72.9%, for the first quarter 2019.
The Company reported GAAP net income of $5.3 million, or diluted earnings per share of $0.10, for the first quarter 2020 compared to GAAP net income of $9.4 million, or diluted earnings per share of $0.18, for the first quarter 2019. On a non-GAAP basis, the Company reported net income of $25.4 million, or diluted earnings per share of $0.48, for the first quarter 2020 compared to non-GAAP net income of $27.6 million, or diluted earnings per share of $0.53, for the first quarter 2019.
Expense Control Measures and 2020 Financial Guidance
On April 14, 2020, NuVasive provided a business update related to COVID-19, including the following temporary actions to reduce operating expenses:
-- Implementing compensation reductions for its board of directors and
executive officers;
-- Controlling discretionary spend across the organization; and
-- Adjusting manufacturing capacity based on certain government directives
and demand, while ensuring sufficient inventory levels to support
current procedure volumes.
Additionally, on April 14, 2020, NuVasive withdrew its annual financial guidance for 2020. The COVID-19 pandemic has had a significant negative impact on elective procedure volumes. As visibility for spine surgery volumes for the remainder of the year is limited, and the Company is not able to predict when or how quickly elective surgery volumes will recover, the Company is not providing further financial guidance for 2020 at this time.
Supplementary Financial Information
For additional financial detail, please visit the Investor Relations section of the Company's website at www.nuvasive.com to access Supplementary Financial Information.
Reconciliation of GAAP to Non-GAAP Information
Management uses certain non-GAAP financial measures such as non-GAAP diluted earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating margin, which exclude amortization of intangible assets, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses from strategic investments, and non-cash interest expense (excluding debt issuance cost). Management also uses certain non-GAAP measures which are intended to exclude the impact of foreign exchange currency fluctuations. The measure constant currency utilizes an exchange rate that eliminates fluctuations when calculating financial performance numbers. The Company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital. Additionally, the Company uses an adjusted EBITDA measure which represents earnings before interest, taxes, depreciation and amortization and excludes the impact of stock-based compensation, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses on strategic investments, and other significant one-time items.
Management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measure.
For the Three Months Ended March 31, 2020
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited - in thousands, except per share data)
Gross Profit
Operating
Net Income Diluted Diluted
Net Income to
Profit EPS WASO 5 Adjusted EBITDA
---
Reported GAAP $188,016 $28,319 $5,298 $0.10 53,727 $5,298
% of revenue 72.3% 10.9%
---
Amortization of intangible assets 12,649 12,649
Litigation related expenses and settlements(1) 3,103 3,103 3,103
Business transition costs(2) (1,440) (1,440) (1,440)
European medical device regulation(3) 1,247 1,247 1,247
Non-cash interest expense on convertible notes 5,724
Net loss on strategic investments 1,411 1,411
Tax effect of adjustments4 (2,562)
Interest expense/(income), net 10,786
Income tax expense 4,827
Depreciation and amortization 34,972
Non-cash stock based compensation (2,858)
---
Adjusted Non-GAAP $188,016 $43,878 $25,430 $0.48 52,532 $57,346
--- ---
% of revenue 72.3% 16.9% 22.1%
---
1 Represents
expenses
associated with
certain ongoing
litigation
matters,
including
infringement of
the Company's
intellectual
property.
2 Costs related to
acquisition,
integration and
business
transition
activities
which include
severance,
relocation,
consulting,
leasehold exit
costs, third
party merger
and
acquisitions
costs,
contingent
consideration
fair value
adjustments,
and other costs
directly
associated with
such
activities.
3 Represents costs
specific to
updating our
quality system,
product
labeling, asset
write-offs and
product
remanufacturing
to comply with
European
medical device
regulation.
4 Represents the
impact from tax
affecting the
adjustments
above at their
statutory tax
rate. As of May
6, 2020, the
Company
estimated an
annual tax rate
of ~27% on a
GAAP basis and
~23% on a non-
GAAP basis.
5 Adjusted non-
GAAP diluted
WASO excludes
the impact of
dilutive
convertible
notes for which
the Company is
economically
hedged through
its anti-
dilutive bond
hedge
arrangements.
For the Three Months Ended March 31, 2019
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited - in thousands, except per share data)
Gross Profit Operating
Net Income Diluted Diluted
Net Income to
Profit EPS WASO 5 Adjusted EBITDA
---
Reported GAAP $200,282 $20,173 $9,386 $0.18 52,480 $9,386
% of revenue 72.9% 7.3%
---
Amortization of intangible assets 13,625 13,625
Litigation related expenses and settlements(1) 3,046 3,046 3,046
Business transition costs(2) 3,833 3,833 3,833
European medical device regulation(3) 332 332 332
Non-cash interest expense on convertible notes 4,319
Tax effect of adjustments4 (6,933)
Interest expense/(income), net 9,104
Income tax expense 1,317
Depreciation and amortization 34,054
Non-cash stock based compensation 5,717
---
Adjusted Non-GAAP $200,282 $41,009 $27,608 $0.53 52,480 $66,789
--- ---
% of revenue 72.9% 14.9% 24.3%
---
(1) Represents
expenses
associated with
certain ongoing
litigation
matters,
including
infringement of
the Company's
intellectual
property.
(2) Costs related to
acquisition,
integration and
business
transition
activities
which include
severance,
relocation,
consulting,
leasehold exit
costs, third
party merger
and
acquisitions
costs,
contingent
consideration
fair value
adjustments,
and other costs
directly
associated with
such
activities.
(3) Represents costs
specific to
updating our
quality system,
product
labeling, asset
write-offs and
product
remanufacturing
to comply with
European
medical device
regulation.
4 Represents the
impact from tax
affecting the
adjustments
above at their
statutory tax
rate. As of May
1, 2019, the
Company
estimated an
annual tax rate
of ~22% on a
GAAP basis and
~23% on a non-
GAAP basis.
5 Adjusted non-
GAAP diluted
WASO excludes
the impact of
dilutive
convertible
notes for which
the Company is
economically
hedged through
its anti-
dilutive bond
hedge
arrangements.
Investor Conference Call
NuVasive will hold a conference call today at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the first quarter 2020. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. After the live webcast, the call will remain available on NuVasive's website through June 6, 2020. In addition, a telephone replay of the call will be available until May 13, 2020. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 13702256.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care and change lives. The Company's less invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes access, implants and fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenue, NuVasive has approximately 2,800 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions you that statements included in this news release or made on the investor conference call referenced herein that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. In addition, this news release contains selected financial results from the first quarter 2020. The Company's results for the first quarter 2020 are prior to the completion of review and audit procedures by the Company's external auditors and are subject to adjustment. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, the impact of the COVID-19 pandemic on the Company's business and financial results; the Company's ability to maintain operations to support its customers and patients in the near-term and to capitalize on future growth opportunities; risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties more fully described in the Company's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
NuVasive, Inc.
Consolidated Statements of Operations
(in thousands, except per share data)
Three Months Ended March 31,
(unaudited) 2020 2019
Revenue
Product revenue $234,687 $243,823
Service revenue 25,194 30,953
Total revenue 259,881 274,776
Cost of revenue (excluding below
amortization of intangible assets)
Cost of products sold 51,645 54,486
Cost of services 20,220 20,008
Total cost of revenue 71,865 74,494
Gross profit 188,016 200,282
Operating expenses:
Sales, marketing and administrative 130,231 145,076
Research and development 18,257 17,575
Amortization of intangible assets 12,649 13,625
Business transition costs (1,440) 3,833
Total operating expenses 159,697 180,109
Interest and other expense, net:
Interest income 731 409
Interest expense (11,517) (9,513)
Other (expense) income, net (7,408) (366)
Total interest and other expense, net (18,194) (9,470)
Income before income taxes 10,125 10,703
Income tax expense (4,827) (1,317)
Consolidated net income $5,298 $9,386
Net income per share:
Basic $0.10 $0.18
Diluted $0.10 $0.18
Weighted average shares outstanding:
Basic 51,837 51,675
Diluted 53,727 52,480
NuVasive, Inc.
Consolidated Balance Sheets
(in thousands, except par values and share amounts)
March 31, 2020
December 31, 2019
ASSETS
(Unaudited)
Current assets:
Cash and cash equivalents $511,976 $213,034
Accounts receivable, net of allowances of
$17,386 and $17,019, respectively 186,826 211,532
Inventory, net 324,675 312,419
Prepaid income taxes 17,628 10,434
Prepaid expenses and other current assets 17,294 16,917
Total current assets 1,058,399 764,336
Property and equipment, net 280,058 266,318
Intangible assets, net 191,136 201,092
Goodwill 559,299 561,064
Operating lease right-of-use assets 107,304 66,932
Deferred tax assets 9,354 9,162
Restricted cash and investments 1,494 1,494
Other assets 13,477 14,892
Total assets $2,220,521 $1,885,290
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued liabilities $91,241 $97,160
Contingent consideration liabilities 14,859 15,727
Accrued payroll and related expenses 40,173 86,458
Operating lease liabilities 7,031 5,567
Income tax liabilities 151 2,005
Senior convertible notes 628,681
Total current liabilities 782,136 206,917
Long-term senior convertible notes 361,633 623,298
Deferred and income tax liabilities 23,905 14,655
Operating lease liabilities 116,496 73,153
Other long-term liabilities 50,152 52,060
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value;
5,000,000 shares authorized, none
outstanding
Common stock, $0.001 par value; 120,000,000
shares authorized at March 31, 2020 and
December 31, 2019, 57,691,871 and
57,524,658 issued and outstanding at March
31, 2020 and December 31, 2019,
respectively 62 62
Additional paid-in capital 1,478,294 1,429,854
Accumulated other comprehensive loss (13,227) (9,418)
Retained earnings 87,773 82,475
Treasury stock at cost; 6,524,218 shares
and 5,379,536 shares at March 31, 2020 and
December 31, 2019, respectively (666,703) (587,766)
Total equity 886,199 915,207
Total liabilities and equity $2,220,521 $1,885,290
NuVasive, Inc.
Consolidated Statements of Cash Flows
(in thousands)
Three Months Ended March 31,
(unaudited) 2020 2019
Operating activities:
Consolidated net income $5,298 $9,386
Adjustments to reconcile net income to net cash provided by operating
activities:
Depreciation and amortization 34,972 34,054
Amortization of non-cash interest 7,143 5,210
Stock-based compensation (2,858) 5,717
Reserves on current assets 5,232 3,785
Net loss on strategic investments 1,411
Other non-cash adjustments 5,403 3,172
Deferred income taxes 9,105 1,547
Changes in operating assets and liabilities, net of effects from
acquisitions:
Accounts receivable 22,409 1,620
Inventory (21,135) (19,292)
Prepaid expenses and other current assets (2,042) (1,399)
Accounts payable and accrued liabilities (5,271) (2,249)
Accrued payroll and related expenses (45,927) (14,815)
Income taxes (8,515) (2,261)
Net cash provided by operating activities 5,225 24,475
Investing activities:
Purchases of intangible assets (2,490) (6,827)
Purchases of property and equipment (28,116) (33,929)
Net cash used in investing activities (30,606) (40,756)
Financing activities:
Purchases of treasury stock (78,818) (8,177)
Payment of contingent consideration (346) (1,435)
Proceeds from issuance of convertible debt, net of issuance costs 437,686
Proceeds from sale of warrants 47,070
Purchase of convertible note hedge (78,300)
Other financing activities (1,233) 1,556
Net cash provided by (used in) financing activities 326,059 (8,056)
Effect of exchange rate changes on cash (1,736) (112)
Increase (decrease) in cash, cash equivalents and restricted cash 298,942 (24,449)
Cash, cash equivalents and restricted cash at beginning of period 214,528 120,235
Cash, cash equivalents and restricted cash at end of period $513,470 $95,786
View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvasive-announces-first-quarter-2020-financial-results-301054196.html
SOURCE NuVasive, Inc.
